Polypharmacy—commonly defined as five or more concurrent medications—is escalating globally, not only in older adults but also in middle‑aged patients [2][4]. Recent analyses show rising rates of adverse drug events (ADEs), hospital admissions, and in‑hospital mortality related to medication harm, with inappropriate polypharmacy identified as a major driver [1][3][6][7]. Updated national guidance (e.g., Scotland’s 2026–2029 polypharmacy guidance) and payer measures are explicitly targeting these risks [5].

Key Rising Safety Issues

1. Increased adverse drug reactions (ADRs) and hospital admissions

Recent studies and reviews show:

• ADRs and ADEs account for up to ~30% of hospital admissions in older adults in some cohorts [3].

• ADR‑related hospital admissions are associated with significantly increased in‑hospital mortality—one large study reports ~2.4‑fold higher odds of death compared with non‑ADR admissions [5].

• A 2026 multi‑institutional study of hospitalized older patients links higher drug counts (5–9 drugs, ≥10 drugs) with longer length of stay and worse outcomes [4].

Implication: The sheer number of drugs, especially in frail older adults, is directly translating into more serious, sometimes fatal, medication harm.

2. Prescribing cascades and inappropriate polypharmacy

Guidance documents and reviews point to prescribing cascades as a particularly concerning mechanism [5][6]:

• An ADE (e.g., edema from a calcium channel blocker) is misinterpreted as a new condition (e.g., heart failure), leading to additional prescriptions (e.g., diuretic).

• Over time, patients accumulate layers of symptom‑treating drugs without reassessment of underlying causes.

The 2026–2029 Scottish polypharmacy guidance explicitly highlights prescribing cascades and “inappropriate polypharmacy” as targets for deprescribing to make medicines “safe, effective and sustainable” [5].

Implication: Clinical workflows seldom require structured medication reviews, allowing cascades to go unnoticed.

3. Drug–drug and drug–disease interactions

Polypharmacy significantly increases:

• Drug–drug interactions (DDIs): heightened risk of arrhythmias, bleeding, CNS depression, renal injury, etc.

• Drug–disease interactions: e.g., NSAIDs worsening heart failure, certain anticholinergics worsening dementia symptoms.

A recent review notes that the likelihood of ADEs rises exponentially with the number of medications, not linearly [6]. Geriatric‑focused analyses emphasize that multimorbidity plus polypharmacy leads to falls, cognitive impairment, and hospitalizations [8][10].

Implication: Polypharmacy amplifies pharmacologic complexity beyond the capacity of usual prescribing checks; dedicated tools and pharmacist input are required.

4. Middle‑aged adults emerging as a high‑risk group

Recent commentary highlights that polypharmacy is no longer just a geriatric issue:

• A 2025 news brief reports polypharmacy is “increasingly common among middle‑aged adults,” driven by earlier onset of chronic conditions (diabetes, hypertension, mental health disorders) and multi‑specialist care [2].

• Population data show rapid rises in adults taking ≥5 medications, reflecting both multimorbidity and aggressive risk‑factor control [3].

Implication: Safety programs that focus solely on 65+ miss a growing cohort of at‑risk 40–64‑year‑olds.

5. Fragmented prescribing and poor in‑home adherence

Recent public health and polypharmacy guidance identify:

• Fragmentation across prescribers and settings (hospital, primary care, specialists), with limited reconciliation at care transitions [4][5].

• In-home complexity: older adults and caregivers struggle with complex regimens, leading to errors, missed doses, or double‑dosing [7].

An umbrella review and WHO’s “Medication Without Harm” initiative highlight polypharmacy as a major driver of non‑adherence, preventable ADEs, and healthcare utilization [9].

Implication: Safety efforts must extend beyond prescribing to include simplification, education, and support for in‑home management.

6. High‑risk medication combinations and new safety measures

2025 Medicare Advantage and other payer programs have introduced polypharmacy‑focused medication safety measures, including:

• Concurrent use of high-risk CNS depressants (e.g., opioids + benzodiazepines + gabapentinoids).

• Excessive anticholinergic burden.

• Overlapping antithrombotics or NSAIDs [5].

Regulators and safety organizations (e.g., ISMP) list polypharmacy and high‑risk combinations among top 2025–2026 patient‑safety concerns [1][5].

Implication: Hospitals and health systems are increasingly incentivized—even financially—to identify and mitigate such regimens.

Counterarguments & Nuances

• Not all polypharmacy is inappropriate. For complex multimorbidity, multiple medications are evidence-based and necessary; the focus should be on inappropriate polypharmacy.

• Aggressive deprescribing without careful planning can lead to destabilization (e.g., rebound hypertension, relapse of depression). Evidence suggests closely supervised deprescribing is safe when done systematically [7].

Implications & Recommended Actions

Hospitals and health systems should:

1. Systematically identify high‑risk polypharmacy

• Use EHR alerts for ≥5 or ≥10 meds plus triggers (falls, confusion, AKI, orthostatic hypotension).

1. Implement regular, structured medication reviews

• Especially at transitions of care (admission, discharge) and for older or multimorbid patients.

1. Adopt deprescribing and cascade‑detection protocols

• Embed tools and clinical pharmacists to systematically assess necessity, benefit–risk, and duplications.

1. Target safety education to middle‑aged adults as well as seniors.

2. Leverage updated national guidance (e.g., 2026–2029 polypharmacy guidance) to standardize “appropriate prescribing” practices [5].